Hausfeld (Washington)

Camila Ringeling

Hausfeld (Washington)

Camila Ringeling is an associate at Hausfeld. Her practice focuses on antitrust, competition, and complex civil and international human rights litigation. Originally from Chile, she joins Hausfeld following a JD at George Mason University’s Antonin Scalia Law School and LL.M.s from Lund University and Georgetown. Camila has worked as consultant for the World Bank Group in the Finance Competitiveness and Innovation Global Practice where she advised client countries on competition policy and regulation. Previously, she worked as a consultant for the Federal Trade Commission’s Office of International Affairs. Prior to her work in the U.S., she was a Senior Associate in mergers and antitrust in Chile’s third largest firm, Barros & Errázuriz. During her tenure, she led high profile mergers, antitrust litigation, and investigations including the largest pharmaceutical merger in Chilean history. She was also involved in several national-level public endeavors including proposed amendments to the Chilean Competition Law, guidelines drafted by the Chilean Competition Authority (FNE) and being a non-governmental advisor at in the International Competition Network. Previously, she was a case handler at the FNE where she led antitrust and merger investigations and the filing of lawsuits before the Competition Tribunal and the Supreme Court. Her European experience includes working at the European Commission’s Directorate General for Competition (DG Comp), Gorrissen Federspiel in Copenhagen, and Howrey LL.P in Brussels. Trained in competition law in the European Union and Latin America, and antitrust in the United States, Camila offers a unique global perspective that enables her to represent clients on complex cross-border issues. Camila is fluent in Spanish.

Linked authors

Hausfeld (London)
Hausfeld (San Francisco)
Hausfeld (London)
Hausfeld (San Francisco)
Hausfeld (Philadelphia)


109 Bulletin

Melinda R. Coolidge, Katie R. Beran, Camila Ringeling The US District Court for the District of Columbia dismisses the FTC’s claims of anticompetitive horizontal agreement involving opioid medication (Endo / Impax)


On March 24, 2022, Judge Royce C. Lamberth of the U.S. District Court for the District of Columbia dismissed the Federal Trade Commission’s (the “Commission”) complaint against Endo Pharmaceuticals Inc. (“Endo”), Impax Laboratories, LLC (“Impax”) and Impax’s owner, Amneal Pharmaceuticals, Inc. (...)


Total visits

Number of readings per contribution

Number of contributions

Author's ranking
In number of contributions
In number of visits
In average number of visits
Send a message